Unlock instant, AI-driven research and patent intelligence for your innovation.

A kind of long non-coding RNA and its application as a molecular marker of multiple myeloma cells

A multiple myeloma, long-chain non-coding technology, applied in the field of monitoring the progress of multiple myeloma, achieving the effect of good repeatability, accurate detection, and low cost

Active Publication Date: 2022-07-01
GENERAL HOSPITAL OF TIANJIN MEDICAL UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Although there have been studies on ncRNAs and the occurrence and progression of multiple myeloma, few studies have analyzed unknown lncRNAs through ceRNA interaction pathways, and studied their biological functions, pathogenic mechanisms, and evaluation of prognosis and progression in MM.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of long non-coding RNA and its application as a molecular marker of multiple myeloma cells
  • A kind of long non-coding RNA and its application as a molecular marker of multiple myeloma cells
  • A kind of long non-coding RNA and its application as a molecular marker of multiple myeloma cells

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0064] 1. 8 cases of bone marrow from patients with multiple myeloma and 2 cases of normal bone marrow were received with 5ml of bone marrow each. After CD138 cells were extracted, the specimens were sent for inspection, and new lncRNAs were screened by RNA sequencing. The results are as follows: figure 1 , predicting its target genes and their GO functions and KEGG biological pathway enrichment analysis ( figure 2 ); candidate miRNAs and mRNAs predicted to interact with lncRNA MSTRG.29039.1 ( Figure 5 A, B).

[0065] 2. Put 3ml of lymphocyte separation solution in a 15ml centrifuge tube, add bone marrow fluid slowly on it, centrifuge at 20°C and 2000rpm for 20 minutes; aspirate the supernatant and collect the mononuclear cell layer (buffy coat) in PBS containing 10ml centrifuge at 1500 rpm for 5 minutes; discard the supernatant, resuspend, count, and centrifuge every 10 7MNCs were resuspended in 80 μl PBS buffer, 20 μl anti-CD138 antibody was added, mixed well and incubat...

Embodiment 2

[0083] An auxiliary diagnosis kit for the progression of multiple myeloma, the kit includes:

[0084] (1), bone marrow mononuclear cell separation reagent (purchased from Solarbio company), multiple myeloma cell CD138 magnetic beads (purchased from Miltenyi Biotec company);

[0085] (2) Specific primers and probes for transcript DNA of lncRNA MSTRG.29039.1;

[0086] (3) Specific primers and probes for GapDH internal reference markers;

[0087] (4), reverse transcriptase, qPCR Mix, 10mM dNT Ps, reverse transcription buffer, RNase inhibitor (purchased from Tiangen company), DEPC water;

[0088] (5), total RNA extraction reagent Trizol (purchased from InvitrogenTM), isopropanol, absolute ethanol, chloroform, PB buffer.

[0089] The specific primers of lncRNA MSTRG.29039.1 are: upstream primer (5'to3'): ACGGAAACAGCCCTGCCTTC (SEQ ID NO:2); downstream primer (5'to3'): CCCTCTCCCTCTCCTGTTGTGG (SEQ ID NO:3).

[0090] The specific primers for the GAPDH internal reference marker are: ...

Embodiment 3

[0092] Human MM cell lines (U266 and AMO-1 cells) were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) and 1% streptomycin-penicillin in a humidified 37°C with 5% CO 2 in the cell incubator. Seed logarithmically grown MM cells into 6-well plates at approximately 1 x 10 per well 6 Cells were transiently transfected with Lipofectamine 3000 reagent according to the manufacturer's instructions. Positive, fluorescent and negative controls (NC) for lncRNA MSTRG.29039.1 (si-MSTRG.29039.1:sense(5'-3')GGAUCGGAAAUGAGAAAUUTT, antisense(5'-3')AAUUUCUCAUUUCCGAUCCTT) were purchased from GenePharma. The specific operations are as follows: Inoculate the cells in 500 μl of antibiotic-free medium, and make them grow to 30-50% confluence during transfection. 2. Preparation of transfection solution, the amount of cells per well is as follows: A. Use 50 μl Opti-MEM low Dilute 20pmol siRNA in serum medium (or other serum-free medium) (the final concentration of siRNA d...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a long-chain non-coding RNA and its application as a molecular marker of multiple myeloma cells. The long-chain non-coding RNA (lncRNA MSTRG.29039.1) has a transcript sequence shown in SEQ ID NO: 1. The present invention discovers for the first time a long-chain non-coding RNA, which is more highly expressed in multiple myeloma cells than normal plasma cells, and is highly expressed in multiple myeloma cell lines. Knockdown of lncRNA MSTRG.29039.1 in cell lines and knockdown of mRNA OSMR can increase cell apoptosis and reduce proliferation. It can be seen that the lncRNA MSTRG.29039.1 can be used as a molecular marker of multiple myeloma cells and is related to the occurrence and progression.

Description

technical field [0001] The invention relates to the field of monitoring the progression of multiple myeloma, in particular to a multiple myeloma cell molecular marker lncRNA MSTRG.29039.1, which can be applied to the occurrence, progression, disease assessment and targeted therapy of multiple myeloma, Provide accurate diagnosis and treatment to patients in order to achieve complete remission and long-term survival. Background technique [0002] Multiple myeloma (MM) is a plasma cell disease characterized by biological heterogeneity. Abnormal function, hypercalcemia, anemia, bone disease and a series of damage. With the use of proteasome inhibitors, the rise of autologous stem cell transplantation ASCT, immunomodulatory agents, monoclonal antibodies and cellular immunity and other immunotherapy, MM patients have achieved deeper remission and prolonged survival, but some patients are still unable to recover. Even many patients still relapse. Therefore, research on the under...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/6886C12N15/113C12N15/11
CPCC12Q1/6886C12Q2600/158C12Q2600/178C12Q2600/166
Inventor 付蓉刘召云刘惠宋嘉丁凯
Owner GENERAL HOSPITAL OF TIANJIN MEDICAL UNIV